Home / News

Health

  • 0

Zenara Pharma launches the first generic of Paxlovid for COVID-19 in India

Zenara Pharma launches the first generic of Paxlovid for COVID-19 in India


·First company to launch the product in the country

·Reduces the risk of death or hospitalization by 89%*

·Pfizer’s Paxlovid is approved by US FDA for COVID treatment

 

Hyderabad, 09 Sep 2022: Hyderabad-based Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, has announced that it has launched Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms of Covid-19. It is to be noted that Zenara Pharma has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product last month. The tablet, which will be sold under the brand name ‘Paxzen’, is being manufactured at Zenara’s US FDA and EU approved state-of-the-art facility in Hyderabad.

 

The product will be sold at a Maximum Retail Price of Rs 5,200 per box, equivalent to one full course of treatment per patient, and contains 20 Tablets of Nirmatrelvir 150ml and 10 Tablets of Ritonavir 100mg.

 

Dr. Jagadeesh Babu Rangisetty, Co-founder and Managing Director at Zenara Pharma, says, “We have launched this product in India with an aim to bring the best treatment options against COVID within reach of patients in our country. Our product, Paxzen, has been proven equivalent to Paxlovid through a Bio Equivalence study, based on which we have received the approval from the regulatory authorities”

 

This product’s breakthrough approval in the US was given by the US FDA in Dec 2021 and is indicated for the treatment of mild-to-moderate COVID-19 in adults. It was the first oral pill that has been approved by US FDA and with a better safety profile than subsequently approved oral therapies and can be self-administered at home, when prescribed. Studies also indicate that the risk of death or hospitalization is reduced by 89%* when taken in a timely manner against COVID.

 

Dr Rangisetty adds, “We have ensured that the product will be available to all patients by placing the product with our distribution partners spread across India and their details can be accessed through our dedicated help line number – 72079 28889 and also through our website. Patients or hospitals may call or whatsapp on this number for availability and we will ensure that they can access Paxzen at the earliest.”

 

Zenara has informed that patients or hospitals may contact this dedicated help line number – 72079 28889  or visit their website www.zenarapharma.com for availability details of Paxzen in their vicinity.

Previous News

Technology News

Combination of 5G, AI, M2M and IoT is bringing the world closer to a connected future

Combination of 5G, AI, M2M and IoT is bringing the world closer to a connected future

IDEMIA whitepaper on IoT/M2M Security Essentials and Trusted Framework

ARTPARK@IISc and Nokia join forces, demonstrate the power of next-generation telecom networks in business communication and automation at IMC 2022

ARTPARK@IISc and Nokia join forces, demonstrate the power of next-generation telecom networks in business communication and automation at IMC 2022

  • The strategic partnership aims to harness AI and ML adva

Invendis to Roll-out 5G Routers and Wi-Fi Solutions ‘Designed’ and ‘Made in India’ in Collaboration with MediaTek

Invendis to Roll-out 5G Routers and Wi-Fi Solutions ‘Designed’ and ‘Made in India’ in Collaboration with MediaTek

NEW DELHI, India – October 02, 2022: Fifth-generation wireless (5G) will potentially be one

KSUM-backed startup gets CERT-IN recognition

KSUM-backed startup gets CERT-IN recognition

Thiruvananthapuram, Oct. 02: Technopark-based cyber security startup Beagle Secu

Latest Business News

LENDINGKART INKS STRATEGIC ALLIANCE WITH CHOLA

LENDINGKART INKS STRATEGIC ALLIANCE WITH CHOLA

̴ To lend business loans to SMEs and MSMEs  ̴

 

Gitex Global 2022: Quixy to bring the idea of No-Code to the masses

Gitex Global 2022: Quixy to bring the idea of No-Code to the masses

Hyderabad, India, 3rd October 2022 – Quixy, the leading no-code platform which has jumped its position from “

Tata Motors registered total sales of 2,43,387 units in Q2FY23; Grows by 42% over Q2FY22

Tata Motors registered total sales of 2,43,387 units in Q2FY23; Grows by 42% over Q2FY22

Mumbai, October 3, 2022: Tata Motors Limited today announced its sales in the domestic & international market, for Q2FY23